We are excited to share our latest update on Alzheimer's research. The LUCIDITY Phase 3 trial, which was built upon the groundbreaking research conducted at Neurology Diagnostics in earlier phases, has shown a 93% reduction in a key biomarker of neurodegeneration. This significant achievement underscores the impact of our collaborative work in moving the needle toward effective Alzheimer’s treatment. As we continue to spearhead advancements in Alzheimer’s, MCI, and MS research, we warmly invite you to refer any suitable patients to Neurology Diagnostics for our upcoming studies.
We are actively seeking participants who are impacted by MCI, Alzheimer’s Disease as well as MS. If you have patients who may be a fit, please reach out or refer them to Neurology Diagnostics.
In the near future, we have exciting studies planned, concentrating on Alzheimer's Disease, Chronic Traumatic Encephalopathy (CTE), and Parkinson's Disease. If you're interested in delving deeper into these studies, please feel free to reach out to us for more information.
We are excited to announce that we have a new referral upload form available for your convenience. You can now easily refer your patients to us by faxing over the attached form. We understand that many practices prefer to share referrals via fax or within your EMR (search: Neurology Diagnostics or Dr.Vandersluis) and we welcome those methods as well. Our goal is to make the referral process as seamless and efficient as possible, so please do not hesitate to reach out to us if you have any questions or feedback. The referral sheet is attached and available for download here.
We are currently accepting new patients for general neurology services. Our experienced team provides comprehensive evaluations and treatments for a wide range of neurological conditions. If you have patients who would benefit from our expertise, we would be honored to provide them with the highest level of care.
Services include (but not limited to):
